Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies

For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Roderburg, Christoph, Özdirik, Burcin, Wree, Alexander, Demir, Münevver, Tacke, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338920/
https://www.ncbi.nlm.nih.gov/pubmed/32647565
http://dx.doi.org/10.2217/hep-2020-0004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338920/
https://www.ncbi.nlm.nih.gov/pubmed/32647565
http://dx.doi.org/10.2217/hep-2020-0004

Ejemplares similares